Skip to main content
    J

    Jupiter Neurosciences, Inc. Common Stock (JUNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.70
    -0.06 (-3.41%)

    Market Cap: $2.32M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jupiter Neurosciences, Inc. Common Stock (JUNS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Jupiter Neurosciences, Inc. Common Stock reported revenue of $21.80K for the fiscal year ended Dec 31, 2025. That year, net income was -$8.64M with a net margin of -39662.8%, operating cash flow was -$5.41M and free cash flow was -$5.41M. The quarter ended Sep 30, 2026 had revenue of $13.94K and net income of -$7.22M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue fell from $1.13M, a compound annual decline of 54.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$21.80KN/A80.6%-40873.2%-39662.8%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$233.28K-63.4%100.0%-1471.4%-2125.2%
    Dec 2021$638.04K-43.3%100.0%-612.4%-686.4%
    Dec 2020$1.13MN/A100.0%-164.4%-146.9%
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$21.80K$0$0$233.28K$638.04K$1.13MN/A
    Cost of revenue$4.23K$0$0N/AN/AN/AN/A
    Gross profit$17.57K$0$0$233.28K$638.04K$1.13MN/A
    Research and development$2.09M$492.66K$954.79K$942.81K$1.45M$1.64M$685.74K
    Operating income-$8.91M-$3.09M-$3.87M-$3.43M-$3.91M-$1.85M-$2.18M
    Net income-$8.64M-$2.44M-$4.78M-$4.96M-$4.38M-$1.65M-$3.05M
    EBITDA-$7.81M-$2.10M-$3.66MN/AN/A-$1.64MN/A
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$13.94K$24.25K$18.65K$21.80K$0$0$0$0$0$0$0$0
    Gross profit$9.61K$21.06K$14.29K$17.57K$0$0$0N/A$0$0$0N/A
    Operating income-$5.80M-$2.74M-$1.96M-$2.81M-$2.30M-$2.26M-$1.54M-$1.47M-$493.55K-$557.08K-$570.70K-$535.64K
    Net income-$7.22M-$2.27M-$2.06M-$2.58M-$2.29M-$2.25M-$1.53M-$1.53M-$591.02K$313.12K-$634.10K-$429.64K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $5.30M exceeded cash and equivalents by $1.51M. Shareholder equity was negative, at -$1.83M, as total liabilities of $7.40M exceeded total assets of $5.56M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$5.56M$6.20M$148.59K$235.94K$667.38K$549.98K$6.18K
    Current assets$4.82M$4.65M$28.74K$69.66K$454.67K$549.98K$4.97K
    Cash and equivalents$3.79M$3.77M$28.48K$64.43K$330.60K$208.00K$1.28K
    Total liabilities$7.40M$2.03M$5.95M$7.38M$5.85M$4.26M$5.02M
    Short-term debt$5.30M$146.43K$2.02M$1.78M$486.80K$108.48K$1.21M
    Long-term debtN/AN/A$106.71KN/AN/AN/AN/A
    Shareholder equity-$1.83M$4.17M-$5.80M-$7.14M-$5.18M-$3.71M-$5.02M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.62M$3.72M$3.95M$5.56M$2.58M$3.97M$4.96M$6.20M$85.55K$136.75K$116.82K$148.59K
    Total liabilities$2.79M$4.08M$6.73M$7.40M$2.52M$2.63M$1.90M$2.03M$5.84M$5.49M$6.14M$5.95M
    Cash and equivalents$300.62K$1.52M$2.36M$3.79M$723.80K$1.88M$2.71M$3.77M$253$14.85K$8.31K$28.48K
    Shareholder equity-$1.16M-$365.97K-$2.78M-$1.83M$57.42K$1.34M$3.06M$4.17M-$5.75M-$5.36M-$6.02M-$5.80M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$5.41M-$3.91M-$480.95K-$1.25M-$1.74M-$254.78K-$142.95K
    Capital expenditures$4$4$3$4$4$0$0
    Free cash flow-$5.41M-$3.91M-$480.96K-$1.25M-$1.74M-$254.78K-$142.95K
    Financing cash flow$5.43M$7.65M$445.00K$982.33K$1.86M$461.50K$107.79K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.72M-$2.29M-$1.43M-$2.37M-$1.15M-$828.22K-$1.06M-$3.70M-$42.60K-$107.46K-$65.17K-$161.14K
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$5$0
    Free cash flowN/AN/A-$1.43M-$2.37M-$1.15M-$828.22K-$1.06M-$3.70M-$42.60K-$107.46K-$65.17K-$161.14K
    Last 12 quarters

    Frequently Asked Questions About JUNS

    What is Jupiter Neurosciences, Inc. Common Stock's annual revenue?

    Jupiter Neurosciences, Inc. Common Stock reported revenue of $21.80K for the fiscal year ended Dec 31, 2025.

    Is Jupiter Neurosciences, Inc. Common Stock profitable?

    No. Jupiter Neurosciences, Inc. Common Stock reported net income of -$8.64M for the fiscal year ended Dec 31, 2025, with a net margin of -39662.8%.

    How much free cash flow does JUNS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.41M minus capital expenditures of $4 produced free cash flow of -$5.41M.

    How much debt does Jupiter Neurosciences, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.30M and cash and equivalents of $3.79M.

    What is JUNS's profit margin?

    For the fiscal year ended Dec 31, 2025, Jupiter Neurosciences, Inc. Common Stock reported gross margin of 80.6%, operating margin of -40873.2% and net margin of -39662.8%.